CVS Health Corporation (CVS)
CVS Health: Undervalued And Ripe For Growth
CVS Health offers a compelling value and income opportunity, trading at a forward P/E under 12 with a 3.4% dividend yield. It delivered strong Q3 results, driven by Aetna's insurance segment and momentum in transparent PBM pricing via CostVantage. Management raised 2025 EPS guidance, projecting robust double-digit earnings growth. It also has a well-covered, growing dividend.
CVS Health reports Q3 earnings beat, raises full-year guidance
CVS Health Corp (NYSE:CVS) reported third quarter 2025 financial results on Wednesday, posting both revenue and adjusted earnings per share (EPS) above Wall Street expectations. For the quarter, CVS reported total revenue of $102.9 billion, up 7.8% from the same period last year and exceeding the consensus estimate of $98.29 billion.
CVS Health (CVS) Reports Q3 Earnings: What Key Metrics Have to Say
The headline numbers for CVS Health (CVS) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
CVS Health Corporation (CVS) Q3 2025 Earnings Call Transcript
CVS Health Corporation ( CVS ) Q3 2025 Earnings Call October 29, 2025 8:00 AM EDT Company Participants Larry McGrath - Executive VP, Chief Strategy Officer & Chief Strategic Advisor to the CEO J. Joyner - President, CEO & Director Brian Newman - Executive VP & CFO Prem Shah - Executive VP & Group President Steven Nelson - Executive VP & President of Aetna Conference Call Participants Lisa Gill - JPMorgan Chase & Co, Research Division Justin Lake - Wolfe Research, LLC Elizabeth Anderson - Evercore ISI Institutional Equities, Research Division Stephen Baxter - Wells Fargo Securities, LLC, Research Division Michael Cherny - Leerink Partners LLC, Research Division Eric Percher - Nephron Research LLC Andrew Mok - Barclays Bank PLC, Research Division George Hill - Deutsche Bank AG, Research Division Kevin Caliendo - UBS Investment Bank, Research Division Presentation Operator Hello, and welcome to CVS Health's Third Quarter 2025 Earnings Call.
CVS Posts Strong Q3 Earnings, but Shares Show Little Movement
CVS reported Q3 financials showing it beat on earnings and revenue, which resulted in strong forward guidance.
CVS Stock Falls Despite Q3 Earnings & Revenue Beat, '25 EPS View Up
CVS shares slip even though Q3 earnings and revenues beat estimates, with the company boosting its 2025 EPS outlook.
CVS Posts Loss on Write-Down, Boosts Guidance
CVS Health raised its guidance for the rest of the year, boosted by improved performance at its Aetna insurance unit.
CVS Health (CVS) Surpasses Q3 Earnings and Revenue Estimates
CVS Health (CVS) came out with quarterly earnings of $1.6 per share, beating the Zacks Consensus Estimate of $1.36 per share. This compares to earnings of $1.09 per share a year ago.
CVS books a $5.7 billion loss in its health-services business, tarnishing upbeat earnings
CVS Health's stock falls as a large charge to write off the value of an underperforming business takes the shine off an otherwise strong earnings report.
CVS Posts Loss on Write-Down, Boosts Guidance
CVS Health raised its guidance for the rest of the year, boosted by improved performance at its Aetna insurance unit.
CVS raises full-year forecast, takes $5.7 billion impairment charge on health clinics
CVS Health raised its annual adjusted profit forecast on Wednesday, aided by improved pharmacy revenues, but also announced a $5.73 billion writedown of healthcare businesses including its in-pharmacy MinuteClinics.
CVS beats estimates, hikes guidance as insurance business improves
CVS Health reported third-quarter earnings and revenue that blew past estimates and raised its adjusted profit outlook, as the company sees improvement in its insurance unit. The quarterly results cap David Joyner's first full year as CEO of the company, which struggled to drive higher profits and improve its stock performance under Karen Lynch.
